Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially ameliorates the risk and is associated with long-term reduction in cardiovascular (CV) events. The robust evidence supporting these therapies supports their continued (and expanding) role in risk reduction. In addition […]

Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different […]

https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4

The 1st ILEP Symposium has come to an end. Finally, we are ready to share the official statistics of this event. Please see the attached graph and map!   We would also like to once again thank our Partners – Sanofi, Viatris and Amgen. Without them this Symposium would not be possible. Thank you so […]

We are pleased to invite you to participate in a free webinar organized by the European Atherosclerosis Society (EAS) together with The Polish Lipid Association, during which we will talk about lipid disorders and rare diseases. We will discuss issues related to the diagnosis, management, treatment and diagnosis of disorders such as familial hypercholesterolemia, familial […]

Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing cardiovascular (CV) events in patients with coronary artery disease (CAD) but produced conflicting results. The aim of this meta-analysis was to evaluate the efficacy and safety of colchicine in patients […]

Familial hypercholesterolaemia (FH) is a genetic and complex multifactorial lipid disorder, which increases the risk of premature atherosclerosis and coronary artery disease. FH is still underdiagnosed and undertreated globally and clinical strategies for the treatment and management of pediatric patients with this disorder are still far from being optimal. The objective of this position paper […]

Fig. 1. Direct potential causes of myocarditis. Myocarditis is an inflammatory disease of the myocardium that mostly affects young adults. The disease is commonly caused by viral infection, medications, autoimmune disorders, and inflammatory conditions. Nearly 50% of the cases of myocarditis are due to post-viral immune response in a setting of an identifiable or non-identifiable […]

A new paper has been published about the association of statin use in older people primary prevention group with risk of cardiovascular events and mortality. The meta-analysis provides a detailed review of existing evidence and observational studies conducted to systematize knowledge on this topic. Please feel invited to learn more about the paper here.

Role of omega-6 and omega-3 fatty acids on inflammatory pathways Based on the available evidence, we are able to delineate specific nutraceuticals that may be important in reducing markers of inflammatory response. ILEP Experts discussed the impact of nutraceuticals on the induction of inflammation. The paper can be accessed here.